SynthesisAnnals of surgical oncology2025
Intraoperative and Postoperative Outcomes of Minimally Invasive Versus Open Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis.
Synthesis in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Laparoscopic left pancreatectomy is safe for the treatment of pancreatic ductal adenocarcinoma treated by chemoradiotherapy compared to open left pancreatectomy: a single-center retrospective study.Surgical endoscopy · 2026Article
- Is Kangduo robotic distal pancreatectomy more economically efficient and effective in postoperative outcomes compared to laparoscopic surgery? A propensity-matched analysis.Journal of robotic surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis systematic review and meta-analysis compared the intraoperative and postoperative outcomes of minimally invasive versus open distal pancreatectomy (ODP) in patients with pancreatic ductal adenocarcinoma (PDAC), which is a highly aggressive tumor with a high mortality rate. Surgical resection remains the only potentially curative treatment. Minimally invasive distal pancreatectomy (MIDP), including laparoscopic and robotic approaches, has gained popularity, although the evidence of its efficacy is limited. MATERIALS AND
methodsPubMed, Scopus, and Web of Science databases were searched for studies that compared MIDP and ODP. Randomized clinical trials (RCTs) and observational studies were included. Risk ratio (RR) and mean difference (MD) with 95% confidence intervals (CI) were used to analyze the outcomes. Heterogeneity was assessed using the I
resultsA total of 20 studies with 9339 patients were included, of which 2219 (23.76%) underwent MIDP and 7120 (76.24%) ODP. MIDP was associated with reduced hospital stay (MD - 1.99; p < 0.000001), infections (RR 0.58; p = 0.001855), delayed gastric emptying (RR 0.48; p = 0.003677), blood loss (MD - 55.55; p = 0.000005), transfusions (RR 0.36; p < 0.000001), and 90-day mortality (RR 0.43; p = 0.001092). Other outcomes, including pancreatic fistula, complications according to the Clavien-Dindo classification, operative time, and reoperation, showed insignificant differences.
conclusionsMIDP for PDAC offers better clinical outcomes than ODP, including reduced infections and transfusions. Further RCTs are needed to validate these findings and update the guidelines.
Indexed as
Identifiers
40913221What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.